Does Immunohistochemistry Provide Additional Prognostic Data in Gastrointestinal Stromal Tumors?

被引:12
|
作者
Demir, Lutfiye [1 ]
Ekinci, Nese [2 ]
Erten, Cigdem [1 ]
Kucukzeybek, Yuksel [1 ]
Alacacioglu, Ahmet [1 ]
Somali, Isil [3 ]
Can, Alper [1 ]
Dirican, Ahmet [1 ]
Bayoglu, Vedat [1 ]
Akyol, Murat [1 ]
Cakalagaoglu, Fulya [2 ]
Tarhan, Mustafa Oktay [1 ]
机构
[1] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, Izmir, Turkey
[3] Dokuz Eylul Univ, Inst Oncol, Dept Med Oncol, TR-35210 Alsancak, Turkey
关键词
Gastrointestinal stromal tumor; immunohistochemistry; predictive potential; prognosis; IMATINIB MESYLATE; C-KIT; GIST; MUTATIONS; SURVIVAL; RECURRENCE; RESISTANCE; DIAGNOSIS;
D O I
10.7314/APJCP.2013.14.8.4751
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To investigate the predictive and prognostic effects of clinicopathologic and immunohistochemical (IHC) features in patients with gastrointestinal stromal tumours (GISTs). Materials and Methods: Fifty-six patients who were diagnosed with GIST between 2002 and 2012 were retrospectively evaluated. Relationships between clinicopathologic/immunohistochemical factors and prognosis were investigated. Results: Median overall survival (OS) of the whole study group was 74.9 months (42.8-107.1 months), while it was 95.2 months in resectable and 44.7 months in metastatic patients respectively (p=0.007). Epitheliolid tumor morphology was significantly associated with shortened OS as compared to other histologies (p=0.001). SMA(+) tumours were significantly correlated with low (<10/50HPF) mitotic activity (p=0.034). Moreover, SMA(+) patients tended to survive longer and had significantly longer disease-free survival (DFS) times than SMA (-) patients (37.7 months vs 15.9 months; p=0.002). High Ki-67 level (>= 30%) was significantly associated with shorter OS (34 vs 95.2 months; 95% CI; p=0.001). CD34 (-) tumours were significantly associated with low proliferative tumours (Ki-67<% 10) (p=0.026). Median PFS (progression-free survival) of the patients who received imatinib was 36 months (27.7-44.2 months). CD34 (-) patients had significantly longer PFS times than that of negative tumours; (50.8 vs 29.8 months; p=0.045). S100 and desmin expression did not play any role in predicting the prognosis of GISTs. Multivariate analysis demonstrated that >= 10/50HPF mitotic activity/HPF was the only independent factor for risk of death in GIST patients. Conclusions: Despite the negative prognostic and predictive effect of high Ki-67 and CD34 expression, mitotic activity remains the strongest prognostic factor in GIST patients. SMA positivity seems to affect GIST prognosis positively. However, large-scale, multicenter studies are required to provide supportive data for these findings.
引用
收藏
页码:4751 / 4758
页数:8
相关论文
共 50 条
  • [21] Prognostic value of Ki67 index in gastrointestinal stromal tumors
    Zhao, Wen-Yi
    Xu, Jia
    Wang, Ming
    Zhang, Zi-Zhen
    Tu, Lin
    Wang, Chao-Jie
    Lin, Tian-Long
    Shen, Yan-Yin
    Liu, Qiang
    Cao, Hui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (05): : 2298 - 2304
  • [22] Prognostic factors of gastrointestinal stromal tumors
    Kovac, D
    Petrovecki, M
    Jasic, M
    Dobi-Babic, R
    Ivanis, N
    Rubinic, M
    Krizanac, S
    Jonjic, N
    Rizzardi, C
    Melato, M
    ANTICANCER RESEARCH, 2002, 22 (03) : 1913 - 1917
  • [23] Gastrointestinal stromal tumors: prognostic factors and therapeutic implications
    Rosa, Fausto
    Alfieri, Sergio
    Tortorelli, Antonio Pio
    Di Miceli, Dario
    Papa, Valerio
    Doglietto, Giovanni Battista
    TUMORI JOURNAL, 2012, 98 (03): : 351 - 356
  • [24] Prognostic impact of preoperative neutrophil-lymphocyte ratio for surgically resected gastrointestinal stromal tumors
    Yang, Jing
    Gu, YuanHui
    Huang, XianBin
    Xu, JiaYu
    Zhang, Yan
    Yang, XiaoJun
    Tian, HongWei
    Zhan, WeiPeng
    MEDICINE, 2019, 98 (16)
  • [25] Lack of prognostic significance of connexin-43 labeling in a series of 46 gastrointestinal stromal tumors
    Boban, Marko
    Ljubicic, Neven
    Nikolic, Marko
    Tomas, Davor
    Zovak, Mario
    Bekavac-Beslin, Miroslav
    Belev, Borislav
    Radic, Jasna
    Milosevic, Milan
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2011, 26 (02) : 124 - 128
  • [26] Gastrointestinal stromal tumors. Diagnosis and treatment
    Acin-Gandara, Debora
    Pereira-Perez, Fernando
    Castano-Pascual, Angel
    Duran-Poveda, Manuel
    Antequera-Perez, Alfonso
    Miliani-Molina, Carlos
    CIRUGIA Y CIRUJANOS, 2012, 80 (01): : 42 - 49
  • [27] Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors
    Iwatsuki, Masaaki
    Harada, Kazuto
    Iwagami, Shiro
    Eto, Kojiro
    Ishimoto, Takatsugu
    Baba, Yoshifumi
    Yoshida, Naoya
    Ajani, Jaffer A.
    Baba, Hideo
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2019, 3 (01): : 43 - 49
  • [28] Molecular response prediction in gastrointestinal stromal tumors
    Cassier, Philippe A.
    Blay, Jean-Yves
    TARGETED ONCOLOGY, 2010, 5 (01) : 29 - 37
  • [29] Gastrointestinal Stromal Tumors: Disease and Treatment Update
    Ho, Maria Y.
    Blanke, Charles D.
    GASTROENTEROLOGY, 2011, 140 (05) : 1372 - U39
  • [30] Advances in Adjuvant Therapy of Gastrointestinal Stromal Tumors
    Adekola, K.
    Agulnik, M.
    CURRENT ONCOLOGY REPORTS, 2012, 14 (04) : 327 - 332